Females with axial spondyloarthritis have longer diagnostic delay and higher burden of the disease. Results from the International Map of Axial Spondyloarthritis (IMAS)

Navarro‐Compán, Victoria, Garrido‐Cumbrera, Marco, Poddubnyy, Denis, Bundy, Christine ORCID: https://orcid.org/0000-0002-5981-3984, Makri, Souzi, Correa‐Fernández, José, Akerkar, Shashank, Lowe, Jo, Karam, Elie and Sommerfleck, Fernando 2024. Females with axial spondyloarthritis have longer diagnostic delay and higher burden of the disease. Results from the International Map of Axial Spondyloarthritis (IMAS). International Journal of Rheumatic Diseases 27 (12) , e15433. 10.1111/1756-185x.15433

PDF - Published Version Available under License Creative Commons Attribution Non-commercial No Derivatives. Download (558kB)

Abstract

Background: To assess gender differences in a large sample of patients included in the International Map of Axial Spondyloarthritis (IMAS) study from around the globe. Method: IMAS is a cross‐sectional online survey (2017–2022) of 5557 unselected axSpA patients from 27 countries. The current analysis assessed differences between males and females for: sociodemographic, health behaviors, disease characteristics, patient‐reported outcomes, mental comorbidities, and treatments. Univariable and multivariable logistic regression analysis was used to evaluate the relationship between gender and disease characteristics, patient‐reported outcomes, comorbidities, and treatments. Results: Data from 5555 patients reporting gender were analyzed: 3492 from Europe, 769 from North America, 600 from Asia, 548 from Latin America, and 146 from Africa. Globally, 55.4% were females, with higher proportions in South Africa (82.2%) and lower in Asia (20.8%). Compared to males, a lower percentage of females smoked and consumed alcohol. The diagnostic delay was significantly longer (+2.4 years) in females, while the frequency of HLA‐B27 positivity of axSpA was lower in females. The use of axSpA pharmacological treatment was more common in females with a higher proportion having ever taken nonsteroidal anti‐inflammatory drugs (NSAIDs), conventional synthetic DMARDs (csDMARDs), and biologic DMARDs (bDMARDS). Conclusions: Identifying the specific disease characteristics associated with gender in patients with axSpA may help to improve the diagnosis and management of the disease, and thereby reduce the disease burden for patients around the world.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Healthcare Sciences
Additional Information:	License information from Publisher: LICENSE 1: URL: http://creativecommons.org/licenses/by-nc-nd/4.0/
Publisher:	Wiley
ISSN:	1756-1841
Date of First Compliant Deposit:	11 December 2024
Date of Acceptance:	18 November 2024
Last Modified:	11 Dec 2024 10:15
URI:	https://orca.cardiff.ac.uk/id/eprint/174678

Actions (repository staff only)

Edit Item